Electrophysiological studies are essential for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), but the utility of nerve conduction studies in monitoring outcomes in individual CIDP patients is controversial. Electrophysiological improvements after short-term treatment have been described in large cohorts of CIDP patients, but the magnitude of the changes is small and might be obscured in individual patients due to the variation inherent in nerve conduction testing. We present the case of a CIDP patient treated successfully with immunosuppression and followed for 31 years with serial standardized clinical and electrophysiological evaluations. Improvement in electrophysiological parameters lagged clinical changes for up to 2 years, but all motor parameters improved (distal motor and F wave latencies, conduction velocities, and compound muscle action potential amplitudes) even with evidence of initial axonal damage. Worsening of electrophysiological parameters, specifically increasing F wave latencies, heralded clinical relapse by as much as a year. Electrophysiological parameters do improve with treatment in CIDP patients, although the changes can take up to 2 years, and also worsening electrophysiological parameters can herald clinical relapse and might help guide therapeutic decisions.

Chronic inflammatory demyelinating polyneuropathy (CIDP) manifests as proximal and distal weakness, areflexia, and sensory impairments progressing for at least 2 months [1]. The diagnosis relies on the clinical presentation and nerve conduction studies (NCS) that show demyelinating neuropathy [2]. The treatment options for CIDP include intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin, plasma exchange, corticosteroids, and other immunosuppressive drugs such as azathioprine [3-5]. Electrophysiological studies are essential for the diagnosis of CIDP, but the utility of NCS in monitoring outcomes in individual CIDP patients is controversial. In large patient cohorts, NCS, an objective measure of disease burden, are associated with clinical deficits [6-9]. Most previous controlled studies in CIDP have been short-term and the capacity for change in NCS may be restricted in such brief time intervals. Despite this consideration, several studies have shown electrophysiological improvement with treatment and correlations with clinical outcomes [6, 7, 9]. In addition, prediction of relapses with changes in NCS has been observed with a higher number of demyelinating changes heralding clinical relapse [8]. Here we present a patient treated for CIDP since 1988 and describe the electrophysiological changes with time in an effort to highlight the benefits and limitations of electrophysiology in CIDP management.

A 25-year-old man presented in 1988 with a 6-month history of progressive numbness, tingling, generalized fatigue, and weakness in the upper and lower limbs. Examination showed grade 4 weakness of elbow, wrist, hand, hip flexor, hamstring, and quadriceps muscles and grade 3 power of more distal muscles in the legs. He had a coarse postural tremor, areflexia, and flexor plantar responses. Sensory testing showed a glove-and-stocking hypesthesia to pinprick and temperature extending to the mid-forearms and knees. Joint position was impaired at the toes and fingertips, and vibration sense was impaired distally in the toes. He had mild bilateral foot-drop gait and walked on a broadened base. He could not perform a tandem gait and the Romberg test was positive. He could not walk on heels or toes.

NCS showed demyelinating polyneuropathy with secondary axonal loss (Table 1). Electromyographic examination showed fibrillation potentials, monophasic positive sharp waves, and reduced recruitment indicating axonal loss. The patient was diagnosed with CIDP and treated with prednisone and azathioprine. He improved clinically over the next 6 months with mild residual weakness, sensory loss, and areflexia, but NCS were unchanged. By 1990, he had more clinical improvement, with improved NCS as shown in Table 1 with increased compound muscle action potential amplitudes and motor nerve conduction velocities as well as decreased distal motor and F wave latencies.

Table 1.

Serial electrodiagnostic studies

Serial electrodiagnostic studies
Serial electrodiagnostic studies

By mid-1992, he was asymptomatic with a normal examination apart from persistent areflexia. By 1993, he was able to play hockey, and prednisone was stopped. As azathioprine was slowly tapered to 25 mg daily by 1995, he remained well clinically, but F wave latencies increased (Table 1). This increase in F wave latencies heralded a clinical relapse in 1996 that responded completely to a higher dose of azathioprine, but the NCS improved more slowly by 1998, although not fully, and he relapsed twice more as azathioprine was tapered.

By 2005 he felt 95–100% of normal, ran 5 miles daily, and worked full time. His upper limb reflexes were normal and he had sluggish knee reflexes. Strength was intact and he had mild distal sensory loss of pinprick. Azathioprine was slowly tapered and stopped in 2011, and by 2012 his NCS were normal (Table 1). He relapsed in 2016 following a respiratory tract infection and responded to IVIG and azathioprine after 10 months when the IVIG was discontinued, although the NCS were unchanged. By late 2018, the patient was 100% of normal with normal strength, hypoactive reflexes in the upper limbs and absent reflexes in the lower limbs, as well as normal sensation and gait. NCS were normal and azathioprine was discontinued in 2019.

There is controversy about the role of NCS in monitoring outcomes of CIDP treatment on a study population and on the patient level [6-9]. Our patient with CIDP was monitored for more than 30 years with serial clinical evaluations and electrophysiology, showing positive, major responses in both after treatment. Generally, the improvements in NCS lagged behind the clinical state for up to 2 years (i.e., 1996–1998), but clearly improved with treatment, and also deteriorated (in 1995) preceding a clinical relapse. This case illustrates that NCS can provide an objective measure of treatment success and also warn of impending clinical relapse. Electrophysiology might serve as a guide when making treatment decisions about tapering effective medications in an apparently clinically stable patient.

CIDP is a chronic condition that needs to be monitored closely. This case illustrates that electrophysiological assessments show delayed recovery after clinical improvement and can predict relapse on an individual patient basis.

The authors would like to thank the patient for his participation in this study.

The authors have no ethical conflicts to declare. The patient gave written informed consent for publication of this case report.

The authors have no conflicts of interest to declare.

No funding was received in the preparation of the manuscript.

P. Khomand performed the chart review and primary composition of the paper. Additionally, V. Bril, H. Katzberg, and P. Khomand performed the literature review for background medical science for this case. M. Ngo contributed to this study with patient testing. V. Bril provided the idea for the paper, supervision, writing and editing assistance, as well as patient care during all encounters.

1.
Van den Bergh
PY
,
Hadden
RD
,
Bouche
P
,
Cornblath
DR
,
Hahn
A
,
Illa
I
, et al.;
European Federation of Neurological Societies
;
Peripheral Nerve Society
.
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision
.
Eur J Neurol
.
2010
Mar
;
17
(
3
):
356
63
.
[PubMed]
1351-5101
2.
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force
.
Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
.
Neurology
.
1991
May
;
41
(
5
):
617
8
.
[PubMed]
0028-3878
3.
Yoon
MS
,
Chan
A
,
Gold
R
.
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy
.
Ther Adv Neurol Disorder
.
2011
May
;
4
(
3
):
193
200
.
[PubMed]
1756-2856
4.
Dyck
PJ
,
O’Brien
P
,
Swanson
C
,
Low
P
,
Daube
J
.
Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy
.
Neurology
.
1985
Aug
;
35
(
8
):
1173
6
.
[PubMed]
0028-3878
5.
Pentland
B
,
Adams
GG
,
Mawdsley
C
.
Chronic idiopathic polyneuropathy treated with azathioprine
.
J Neurol Neurosurg Psychiatry
.
1982
Oct
;
45
(
10
):
866
9
.
[PubMed]
0022-3050
6.
Bril
V
,
Katzberg
H
,
Donofrio
P
,
Banach
M
,
Dalakas
MC
,
Deng
C
, et al.
ICE Study Group. Electrophysiology in chronic demyelinating polyneuropathy with IGIV
.
Muscle Nerve
.
2009
Apr
;
39
(
4
):
448
55
.
[PubMed]
0148-639X
7.
Bril
V
,
Banach
M
,
Dalakas
MC
,
Deng
C
,
Donofrio
P
,
Hanna
K
, et al.;
ICE Study Group
.
Electrophysiologic correlations with clinical outcomes in CIDP
.
Muscle Nerve
.
2010
Oct
;
42
(
4
):
492
7
.
[PubMed]
0148-639X
8.
Chin
RL
,
Deng
C
,
Bril
V
,
Hartung
HP
,
Merkies
IS
,
Donofrio
PD
, et al.
Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: comparison of patients with and without subsequent relapse
.
Muscle Nerve
.
2015
Oct
;
52
(
4
):
498
502
.
[PubMed]
0148-639X
9.
Dyck
PJ
,
Litchy
WJ
,
Kratz
KM
,
Suarez
GA
,
Low
PA
,
Pineda
AA
, et al.
A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
.
Ann Neurol
.
1994
Dec
;
36
(
6
):
838
45
.
[PubMed]
0364-5134
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.